S100A9 and acute myeloid leukemia: Taken together, tasquinimod affects AML cell survival and proliferation similar to gene silencing, by targeting mTOR-ER stress signaling, indicating the therapeutic potential of S100A9 as a novel target for the treatment of AML patients.